0

 

 2017³â ´ëÇÑÀüÇØÁúÇÐȸ Ãá°è Çмú´ëȸ
ÀÏ ½Ã 2017³â 6¿ù 24ÀÏ ¿ÀÈÄ 1 ½Ã30ºÐ - 5½Ã 30ºÐ
Àå ¼Ò Àü³²´ëÇб³ Àǰú´ëÇÐ ´öÀçȦ
Program  
Session I Hot topics of Hypertension ÁÂÀå: ÀÌÅ¿ø(°æÈñ´ë),
ÀÓõ±Ô(°æÈñ´ë)
1:30-2:00 Çѱ¹Çü °íÇ÷¾Ð Áø·á Áöħ À̼ҿµ(Â÷ÀǰúÇдë)
2:00-2:30 Hypertension and Kidney : Criminal or Victim ±è¼¼Áß(¼­¿ï´ë)
2:30-3:00 Hypertension in CKD : Beyond the guidelines ÀÌ»óÈ£(°æÈñ´ë)
3:00-3:20 Panel discussion: ¹èÀºÈñ (Àü³²´ë),
·ùµ¿¿­(ÀÌÈ­¿©´ë),
Á¤°æÈ¯(°æÈñ´ë),
¸¶¼º±Ç(Àü³²´ë)
3:20-3:30 Coffee Break  
Session II Hypertension in the real world ÁÂÀå: ±è±ÙÈ£(ÇѾç´ë),
±è¼ö¿Ï(Àü³²´ë)
3:30-4:00 Elderly hypertension: Target BP and Drug of Choice ÃÖÈ«»ó(Àü³²´ë)
4:00-4:30 Class effect with Anti-hypertensive medications : Clinical considerations °­°æÇ¥(ÀüºÏ´ë)
4:30-5:00 Control of BP for CKD in the real world: Case review ¹ÚÁ¾ÇÏ(¿ï»ê´ë)
5:00-5:20 Panel discussion: ±è¼º±Õ(ÇѸ²´ë),
¹®ÁÖ¿µ(°æÈñ´ë),
ÃÖ´ëÀº(Ãæ³²´ë),
±è⼺(Àü³²´ë)
5:20-5:30 Closing  

 2015³â ´ëÇÑÀüÇØÁúÇÐȸ Ãß°è Çмú´ëȸ
ÀÏ ½Ã 2015³â 11¿ù 22ÀÏ (ÀÏ) 09:00 ~ 16:00
Àå ¼Ò °æÈñ´ëÇб³ Á¾ÇÕ°­Àǵ¿(û¿î°ü) ÁöÇÏ1Ãþ ´ë°­´ç
Program
Á¦ 13ȸ °æÈñ ½ÅÀå ¿¬¼ö°­ÁÂ
  I. Omics Research in Kidney Disease ÁÂÀå: ±è±¤Ç¥(°æÈñ´ë),
ÀÓõ±Ô(°æÈñ´ë)
09:00-09:30 Genomics:GWAS in IgA nephropathy Á¤°æÈ¯(°æÈñ´ë)
09:30-10:00 Transcriptomics in kidney disease ÀÌ»óÈ£(°æÈñ´ë)
10:00-10:30 Proteomic research in glomerular disease and transplantation ±èÂù´ö(°æºÏ´ë)
10:30-10:50 Coffee Break  
  II. Old and New in Glomerular Disease ÁÂÀå:±è¿µÈÆ(ÀÎÁ¦´ë),
ÀÌÅ¿ø(°æÈñ´ë)
10:50-11:20 »ç±¸Ã¼ Áúȯ ÀÓ»ó Áø´ÜÀÇ Tips ÀÓõ±Ô(°æÈñ´ë)
11:20-11:50 New discovery of etiology:Role of Infection and autoimmunity ±è¾ç±Õ(°æÈñ´ë)
11:50-12:20 Emerging therapeutic modality:From steroid to new biologic agent ±è¼¼¿¬(°æÈñ´ë)
15:00-15:20 Coffee Break  
´ëÇÑÀüÇØÁúÇÐȸ Ãß°è Çмú´ëȸ
  Á¦1ºÎ Interesting Topic ÁÂÀå: Çϼº±Ô(¿¬¼¼´ë),
ÀÌÁ¾Àº(Àü³²´ë)
13:30-14:00 ¸¸¼º»ç±¸Ã¼½Å¿°ÀÇ °íÇ÷¾Ð:º´Àΰú Ä¡·á ÀÓõ±Ô(°æÈñ´ë)
14:00-14:30 ½ÅÁõÈıº ȯÀÚÀÇ ÀÌ´¢Á¦ Ä¡·á ±è⼺(Àü³²´ë)
14:30-15:00 Salt sensitivity-Endothelial dysfunction ÃÖÈÆ¿µ(¿¬¼¼´ë)
15:00-15:20 Coffee Break  
  Á¦2ºÎ Interesting Case ÁÂÀå:±ÇÅÂȯ(°æºÏ´ë),
±è¼ö¿Ï(Àü³²´ë)
15:20-15:40 Familial renal hypouricemia with acute kidney injury ±èÁø¼÷(°æÈñ´ë)
15:40-16:00 Chronic hypokalemia and nephrocalcinosis ÀÌ¿ë±Ô(±¹¹Î °Ç°­º¸Çè Àϻ꺴¿ø
16:00 closing Remark  

 2013 Á¦7ȸ ´ëÇÑÇ÷¾×Åõ¼®¿©°ú¿¬±¸È¸ ½ÉÆ÷Áö¾ö
ÀÏ ½Ã 2013³â 7¿ù 28ÀÏ (ÀÏ) 08:00 ~ 15:30
Àå ¼Ò °Ç±¹´ëÇб³º´¿ø ´ë°­´ç
Program
Online Hemodilafiltration: A to Z
08:00-08:50 Registration
08:50-09:00 Opening Remarks - ´ëÇÑÇ÷¾×Åõ¼®¿©°ú¿¬±¸È¸ ȸÀå ÇÏ ¼º ±Ô
  Ãà »ç - °Ç±¹´ëÇб³ ÀÇ·á¿øÀå ¾ç Á¤ Çö
I. Technical Aspects of Online-HDF - ÁÂÀå:ÀÌÈ£¿µ.À±¿µ¼®
09:00-09:30 Basic Equipments and Principles of Online-HDF - ÇѾçÀÇ´ë ÀÌ Ã¢ È­
09:30-10:00 Water Treatment in Online-HDF:Microbiological Quality - Àϻ꺴¿ø ½Å¼®±Õ
10:00-10:30 Anticoagulation in Online-HDF - °Ç±¹ÀÇ´ë Á¶¿µÀÏ
10:30-10:50 COFFEE Break
II. Clinical Aspects of Online-HDF (1) - ÁÂÀå:ÀÌÅ¿ø.±èÇöö
10:50-11:20 Nutrition in Onlinep-HDF - ÀÎÇÏÀÇ´ë À̽¿ì
11:20-11:50 Substitional Fluid of Online-HDF:Pre-dilution vs. Post-dilution - ÀÎÁ¦ÀÇ´ë ±è¾ç¿í
11:50-12:20 Standard Prescription of Online-HDF - Àü³²ÀÇ´ë ±è⼺
12:20-13:20 Lunch
III. Clinical Aspects of Online-HDF (2) - ÁÂÀå:Çϼº±Ô.À̼ºÁÖ
13:20-13:50 Clinical Benefits, Including QOL and Long-term Mortality, of Online-HDF - ¿ï»êÀÇ´ë ÀåÀç¿ø
13:50-14:20 Which Patients Could Benefit from Online-HDF?:Learanig from Cases
14:20-14:50 New Modality of Online-HDF

14:50-15:20

Futures of Online-HDF and Renal Replacement Therapy

15:20-15:30 Closing Remarks

 2011 ´ëÇÑÀüÇØÁúÇÐȸ Ãß°èÇмú´ëȸ
ÀÏ ½Ã 2011³â 10¿ù 8ÀÏ (Åä)
Àå ¼Ò Á¦ÁÖ ¼­±ÍÆ÷ ÄÁº¥¼Ç¼¾ÅÍ
´ëÇÑÀüÇØÁúÇÐȸ(±èÈ£Áß, ±è±ÙÈ£)
13:00 - 13:20 Renal ammonia metabolism: acidosis vs. chronic hypokalemia - ÀÌÈ­¿©ÀÚÀÇ´ë ÇØºÎÇÐ Çѱâȯ
13:20 - 13:40 Dietary sodium in take in chronic kidney disease - ÇѾçÀÇ´ë ³»°ú ±è±ÙÈ£
13:40 - 14:00 ACE2 and angiotensin 1 -7 in hypertensive renal disease - °æÈñÀÇ´ë ³»°ú ¹®ÁÖ¿µ
14:00 - 14:20 V2 receptor antagonist - ÇѾçÀÇ´ë ³»°ú ÀÌÁÖÇÐ

 2010 ´ëÇÑÀüÇØÁúÇÐȸ Ãß°èÇмú´ëȸ
ÀÏ ½Ã 2010³â 10¿ù 9ÀÏ (Åä)
Àå ¼Ò ´ë±¸ EXCO
´ëÇÑÀüÇØÁúÇÐȸ(±èÈ£Áß, ±è±ÙÈ£)
13:00 - 13:30 ICU¿¡¼­ ÈçÈ÷ Á¢ÇÏ´Â ÀüÇØÁú ÀÌ»ó°ú Ä¡·á¿¡ °üÇÑ ÃÖ½ÅÁö°ß - Áß¾ÓÀÇ´ë ³»°ú ÀÌÀç¿í
13:30 - 14:00 Emerging role of Akt substrate protein AS169 in the regulation of AQP2 translocation (´ëÇÑÀüÇØÁúÇÐȸ ¿¬±¸ºñ °á°ú ¹ßÇ¥) - °æºÏÀÇ´ë »ý¸®ÇÐ ±ÇÅÂȯ
14:00 - 14:30 ICU¿¡¼­ ÈçÈ÷ Á¢ÇÏ´Â »ê-¿°±â ÀÌ»ó°ú Ä¡·á¿¡ °úÇÑ ÃÖ½ÅÁö°ß - ¼­¿ïÀÇ´ë ³»°ú ¿ÀÀ±±Ô

 2010 Á¦ 8ȸ(2010³â, ´ëÇÑÀüÇØÁú ÇÐȸ)Á¤±âÇмú´ëȸ (APCN SEOUL°ú °°ÀÌ)
ÀÏ ½Ã 2010³â 6¿ù 7ÀÏ (¿ù)
Àå ¼Ò COEX Convention Center

 2009 ´ëÇÑÀüÇØÁúÇÐȸ Ãß°èÇмú´ëȸ
ÀÏ ½Ã 2009³â 10¿ù 17ÀÏ (Åä)
Àå ¼Ò ÀüºÏ (¹«ÁÖ¸®Á¶Æ® Ƽ·ÑÈ£ÅÚ)
   
  1. Free Communication
  Oral rehydration therapy for acute diarrheal disease - °æÈñÀÇ´ë ±è¼ºµµ
  2. Symposium
  ¸¸¼º ¿ïÇ÷¼º ½ÉºÎÀü¿¡¼­ ¼öºÐ ÀüÇØÁú Àå¾Ö ¹× ½Å±â´É ÀÌ»ó - Àü³²ÀÇ´ë ¸¶¼º±Ç
  ¸¸¼º °£Áúȯ¿¡¼­ ¼öºÐ ÀüÇØÁú Àå¾Ö ¹× ½Å±â´É ÀÌ»ó - Áß¾ÓÀÇ´ë ÀÌÀç¿í
  ±Þ ¸¸¼º ³úÁúȯ¿¡¼­ ¼öºÐ ÀüÇØÁú Àå¾Ö ¹× ½Å±â´É ÀÌ»ó - ¼­¿ïÀÇ´ë ±èµ¿±â

 2009 Á¦ 7ȸ Á¤±âÇмú´ëȸ
ÀÏ ½Ã 2009³â 5¿ù 9ÀÏ (Åä), ¿ÀÈÄ 1½Ã
Àå ¼Ò ÇѾç´ëÇб³ °è´Ü°­Àǵ¿ ¼¼¹Ì³ª½Ç
   
13:30-14:00 1. Free communication
14:00-14:30 Ubiquitination of renal aquaporin-2 - ±ÇÅÂȯ °æºÏÀÇ´ë
14:30-15:00 Expression of the ammonia transporter family members, Rh B glycoprotein and Rh C glycoprotein, in the kidney - Çѱâȯ ÀÌÈ­ÀÇ´ë
15:00-15:30 Bedside Approach to acid-base disturbance : Is newer approach better ?
- ÀÌ¿µ¼÷ À»ÁöÀÇ´ë
15:30-16:00 Coffee Break
16:00-16:30 Renal handling of Ammonium and acid - base regulation - ±èÇý¿µ ÃæºÏÀÇ´ë
16:30-17:00 Acquired Gitelman's syndrome - ±è¿ë±Õ °¡Å縯ÀÇ´ë ¼º°¡º´¿ø
17:00-17:30 Role of pendrin in acid-base regulation - ±è¼¼Áß °¡ÃµÀÇ¿ø

 2008 Ãß°è Çмú´ëȸ Çà»ç¾È³»
ÀÏ ½Ã 2008³â 10¿ù 18ÀÏ (Åä), ¿ÀÈÄ 1:00-2:30
Àå ¼Ò ´ëÀü ÄÁº¥¼Ç¼¾ÅÍ (´ëÇѽÅÀåÇÐȸ Ãß°èÇмú´ëȸ ±â°£ ³»)
   
13:00~13:30 1. Free Communications
  2. Symposium : Divalent Ions and Kidney
13:30~13:50 Calcium metabolism --POSTECH ÀüÀº½Ç
13:50~14:10 Magnesium metabolism --ÇѸ²ÀÇ´ë ¼­Àå¿ø
14:10-14:30 Phosphate metabolism --°Ç¾çÀÇ´ë ÃÖ³«¿ø

 2008 Á¦6ȸ Á¤±âÇмú´ëȸ
ÀÏ ½Ã 2008³â 3¿ù 15ÀÏ
Àå ¼Ò  
   
  Rosiglitazone prevents impaired renal function and dysregulation of sodium transporters in DOCA-Salt hypertensive (DSH) rats - Àü³²ÀÇ´ë ¹èÀºÈñ
  Renal AQP2, ENaC, and NHE3 in rats with experimentally induced heart failure is reversed by angiotensin II type 1 receptor antagonism - Sophie C.
  Renin-antiogensin system-considerations for hypertension and kidney - °í´ëÀÇ´ë ÀÓÇüÀº À¯±âȯ
  Vasopressin and vasopressin receptor antagonists - ¼­¿ïÀÇ´ë ¿ÀÀ±±Ô
  Nitric oxide in the kidney: Its physiological role and pathophysiological implications - Àü³²ÀÇ´ë »ý¸®ÇÐ ÀÌÁ¾Àº
  Renal effects of Prostaglandins and cyclooxygenase-2 inhibitors - ÇѾçÀÇ´ë ±è±ÙÈ£
  The role of aniopoietin-1 in kidney disease - ÀüºÏÀÇ´ë ±è¿ø

 2007 Á¦5ȸ Á¤±âÇмú´ëȸ
ÀÏ ½Ã 2007³â 3¿ù 31ÀÏ (Åä)
Àå ¼Ò ÇѾç´ëÇб³º´¿ø °è´Ü°­Àǵ¿ 401È£ ¼¼¹Ì³ª½Ç
   
  Free Communication
  Ç×ÀÌ´¢ È£¸£¸ó°ú ¾ÈÁö¿ÀÅٽŠII°¡ ÁýÇÕ°ü »óÇǼ¼Æ÷¿¡¼­ ¼öºÐÅë·ÎÀÇ ¼¼Æ÷³» ¼ö¿¡ ¹ÌÄ¡´Â »óÈ£ÀÛ¿ë - °æºÏÀÇ´ë ±ÇÅÂȯ
  Regulation of urea transporter by the TonEBP - Ãæ³²ÀÇ´ë Á¤ÁÖ¿µ
  ±Þ¼º ½ÅºÎÀü ½ÅÀå¿¡¼­ antioxidantÀÇ È¿°ú - Àü³²ÀÇ´ë ¹èÀºÈñ
  Clinical Science Symposium
  ´ë»ç¼º »êÁõÀ» µ¿¹ÝÇÑ ³»¿ø ȯÀÚ¿Í Ç÷¾×Åõ¼® ȯÀÚ¿¡¼­ Albumin/Lactate Corrected Anion Gap°ú Strong lon Gap(SIG)ÀÇ ÀÓ»óÀû ÀÇ¹Ì¿Í Àû¿ë - À»ÁöÀÇ´ë ÀÌ¿µ¼÷
  Normotensive hypokalemic disorders - ¼­¿ïÀÇ´ë ÇÑÁø¼®
  Hypertensive hypokalemic disorders - ÀÌÈ­ÀÇ´ë ÃÖ±Ôº¹

 2006 ´ëÇÑÀüÇØÁúÇÐȸ Ãß°èÇмú´ëȸ
ÀÏ ½Ã 2006³â 10¿ù 14ÀÏ (Åä)
Àå ¼Ò °æÁÖ Çö´ëÈ£ÅÚ (´ëÇѽÅÀåÇÐȸ Ãß°èÇмú´ëȸ ±â°£ ³»)
   
  Free Communication
  Primary aldosteronism in a patient with ESRD
ÀÎÁ¦ÀÇ´ë ¼­¿ï¹éº´¿ø ³»°ú ³ªÇöÈñ
  Mannitol-induced metabolic alkalosis
ÀüºÏÀÇ´ë ³»°ú °­°æÇ¥
  Clinical Symposium : Dysnatremia
  Hyponatremia: management errors - ÇѸ²ÀÇ´ë ³»°ú ¼­Àå¿ø
  Pseudohyponatremia: Does it matter in current clinical practice? - ÇѾç´ë³»°ú ±è±ÙÈ£
  Hypernatremia: Successful Treatment - Àü³²ÀÇ´ë ³»°ú ±è¼ö¿Ï

 2006 Á¦ 4ȸ Á¤±âÇмú´ëȸ
ÀÏ ½Ã 2006³â 3¿ù 25ÀÏ(Åä), ¿ÀÈÄ 1½Ã
Àå ¼Ò °¡Å縯ÀǰúÇבּ¸¿ø 1002È£
   
Program
  Free Communication
  Electrolyte & Blood Pressure topics
Symposium
  1. NO synthesis in the kidney - ÀÌÈ­ÀÇ´ë ÇØºÎÇб³½Ç Çѱâȯ
  2. Introduction of organic anion transporters and an regulatory mechanism by
caveolins - ÀÎÇÏÀÇ´ë ¾à¸®ÇÐ Â÷¼®È£
  3. Urea transporters in the kidney - °¡Å縯ÀÇ´ë ¼Ò¾Æ°ú ±èµ¿¾ð
  4. Dysregulation of ENaC in animal models of NS & LC - Àü³²ÀÇ´ë ³»°ú ±è¼ö¿Ï
  5. The role of angiotensin ll in renal interstitial injury - ÀÎÁ¦ÀÇ´ë ¼Ò¾Æ°ú ±¸ÀÚ¿í
  ÅðÀÓ Æ¯º°°­¿¬: ÀüºÏÀÇ´ë ³»°ú °­¼º±Í
  The kidney knows the answers to the hidden message in the water

 2005³â Ãß°èÇмú´ëȸ
ÁÖ Á¦ Potassium homeostasis
ÀÏ ½Ã 2005³â 10¿ù 8ÀÏ(Åä), ¿ÀÈÄ 2½Ã 10ºÐ - 3½Ã 30ºÐ
Àå ¼Ò Á¦ÁÖ ¶ó¸¶´ÙÇöóÀÚÈ£ÅÚ ÇѶóȦ
   
Program
  1. Dietary potassium intake in Korean population - ÇѾç´ë »ýȰ°úÇдëÇÐ ½Äǰ¿µ¾çÇаú ¾ö¾Ö¼±
  2. Regulation of potassium excretion in the kidney - Àü³²ÀÇ´ë »ý¸®Çб³½Ç ÀÌÁ¾Àº
  3. Physiology & pathophysiology of transcellular shift of potassium balance -
¼­¿ïÀÇ´ë ³»°ú ³ª±â¿µ
  4. Hyperkalemia in chronic renal failure - ÇѾçÀÇ´ë ³»°ú ÇÑ»ó¿õ

 2005³â Á¦ 3ȸ Á¤±âÇмú´ëȸ
ÁÖ Á¦ Potassium homeostasis
ÀÏ ½Ã 2005³â 3¿ù 5ÀÏ(Åä), ¿ÀÈÄ 12½Ã 30ºÐ
Àå ¼Ò °¡Å縯´ëÇб³ ÀǰúÇבּ¸¿ø, 1002È£½Ç
   
Program
1:30-2:00 Free communications
  Electrolyte & Blood Pressure topics
2:30-4:00 Symposium I
  Studies of sodium transporters using cell culture models Àü³²¼öÀÇ´ë ÇÑÈ£Àç
  K/O mouse models in salt retention and hypertension °í½ÅÀÇ´ë ¾ÈµµÈ¯
  Adrenomedullin and the kidney ÀüºÏÀÇ´ë ±è ¿ø
4:30-6:00 Symposium II
  Renal sodium handling and hypertension ÀÎÁ¦ÀÇ´ë ±è¾ç¿í
  Dietary salt and potassium intake and hypertension °¡Å縯ÀÇ´ë À̽ÂÇå
  Dysregulation of BP in diseased kidneys ¼­¿ïÀÇ´ë Áֱǿí

 2004³â Á¦ 2ȸ Á¤±âÇмú´ëȸ
ÀÏ ½Ã 2004³â 2¿ù 21ÀÏ(Åä)
Àå ¼Ò °¡Å縯´ëÇб³ ÀǰúÇпø 1002È£½Ç, ¼­¿ï
   
Program
1:30-2:00 Molecular Pathogenesis of Nephrogenic Diabetes Insipidus - ¼­¿ïÀÇ´ë Á¤ÇØÀÏ
2:00-2:30 Renal Hypophosphatemic Rickets (Osteomalacia) - ¼­¿ïÀÇ´ë ÃÖ ¿ë
2:30-3:00 Bartter¡¯s & Gitelman¡¯s syndrome - Àü³²ÀÇ´ë ÃÖ±âö
3:00-3:40 State of the Art Lecture: Management of Hyperkalemia in ESRD - Nippon Medical School, Yasuhiko Iino
3:40-4:00 Coffee break
4:00-4:30 Oxidative Stress and the Kidney - ÇѸ²ÀÇ´ë ±¸ÀÚ·æ
4:30-5:00 Heme Oxygenase in Kidney Disease - °æ»óÀÇ´ë À弼ȣ
5:00-5:30 Osmotic Stress and the Kidney - ¼­¿ïÀÇ´ë ³ª±â¿µ
5:30-6:00 Natriuretic Peptides in the Kidney in Hypertension - Àü³²ÀÇ´ë ÀÌÁ¾Àº
6:30 ÆòÀÇ¿øÈ¸; ¸Þ¸®¾îÆ® È£ÅÚ

 2003³â Á¦ 1ȸ Á¤±âÇмú´ëȸ
ÀÏ ½Ã 2003³â 3³â 8ÀÏ(Åä)
Àå ¼Ò °¡Å縯´ëÇб³ ÀǰúÇпø 1002È£½Ç
   
Program
  SESSION I Reviews
  ³×ÇÁ·ÐÀÇ ÇØºÎÇÐ - °¡Å縯´ë ±è Áø
  Renal Aquaporins - µ¿±¹´ë ±ÇÅÂȯ
  ½Å¼¼°üÀÇ ¿î¹Ýü - ÇѸ²´ë ±è±ÙÈ£
  Urine Acidification Test - °¡Å縯´ë ÀåÀ±½Ä
  ½ÅÀå¿¡¼­ ÀÌ´¢È£¸£¸óÀÇ »ý¸® ¹× º´Å»ý¸® - Àü³²´ë ±è¼ö¿Ï
  SESSION II Case Reports
  Herbal Nephropathy - ÇѾç´ë ÇÑ»ó¿õ
  Gitelman Syndrome - ¿ø±¤´ë ¼ÛÁÖÈï
  Hypokalemic Paralysis associated with Sjogren`s syndrome - °í·Á´ë Ç¥ÈñÁ¤
  Gitelman Syndrome - ÀüºÏ´ë ±è ¿ø